type 2 diabetes mellitus
Conditions
Interventions
None listed
Sponsors
Toho University Omori Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are included in this study; 1. Patients with diabetes who used Rybelsus at least once till 2023/4/20 2. Patients aged 18 years or older at the initiation of this study (at approval by institutional review board)
Exclusion criteria
Exclusion criteria: Patients who fall into any of the following criteria are excluded from participating in the study; 1. Patients with type 1 diabetes mellitus 2. Patients with excessive drinking of alcohol (net alcohol intake is more than 60g/day for male or 30g/day for female) 3. Patients with dementia 4. Patients who were pregnant during data collection period 5. Patients who were hospitalized for blood glucose management for a week or longer within 12 weeks before and after the index date 6. Patients with poor medication adherence (judged by attending physician) 7. Patients who were started on Reversus at another hospital 8. Patients with other conditions that the attending physician think inappropriate to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c | — |
Secondary
| Measure | Time frame |
|---|---|
| Value or amount/percentage change of the following items; - Major blood tests - Other general blood tests - vital signs - body weight, BMI Percentage of patients achieving <7% HbA1c Time taken from the start of 3 mg to 14mg of Rybelsus Questionnaire results on reasons for increasing dose to 14 mg of Rybelsus | — |
Countries
Japan
Contacts
Public ContactGenki Sato
Toho University Omori Medical Center Diabetes, Metabolism and Endocrinology Center
Outcome results
None listed